Skip to main content
Premium Trial:

Request an Annual Quote

Lion, Sated from NetGenics Acquisition, Removes Tripos From Its Plate

NEW YORK, Feb 7 - For Lion Bioscience, it's in with the new chemoinformatics platform and out with the old.

 

The German bioinformatics firm has liquidated its investment in drug-discovery chemistry company Tripos, both firms said in separate statements on Thursday. The move, which netted Lion roughly $22.5 million, comes just one month after Lion acquired NetGenics, which integrates bioinformatic and chemoinformatics.

 

Lion sold 812,182 shares of Tripos common stock in a block trade handled by UBS Warburg. As a result of the sale, Tripos' public float increased to approximately 8.4 million shares from about 7.6 million shares.

Lion also terminated its investor rights agreement and gave up the right to designate a Tripos director.

 

"Following our recent acquisition of NetGenics, Lion now has all of the elements for delivering an industry-leading data and application integration platform for the Life Sciences industry," Friedrich von Bohlen, Lion's CEO, said in his statement. "As a result, we no longer consider our investment in Tripos to be of strategic value."

 

In October 2000, the two companies struck a $25 million agreement to provide Bayer with a drug and agricultural chemistry research platform that would integrate Tripos' chemoinformatics technology with Lion's SRS data integration system. That agreement included an up-front payment, licensing fees, R&D funding, and milestone payments.

 

This working relationship between the two companies would not change, Tripos CEO and President John P. McAlister stressed in his statement. "We continue to work closely with Lion on our collaboration with Bayer to create an integrated chemoinformatics technology platform to speed Bayer's identification of lead candidates for its drug and agricultural chemical programs," he said.

 

Von Bohlen agreed: "Lion is committed to continuing its collaboration with Tripos in providing Bayer with a pharmacophore informatics platform to accelerate Bayer's drug-discovery activities.'' Lion is the project leader of this collaboration.

 

Tripos' technology allows researchers to analyze structure-activity relationships in molecules through three-dimensional molecular modeling.

The Scan

Germline-Targeting HIV Vaccine Shows Promise in Phase I Trial

A National Institutes of Health-led team reports in Science that a broadly neutralizing antibody HIV vaccine induced bnAb precursors in 97 percent of those given the vaccine.

Study Uncovers Genetic Mutation in Childhood Glaucoma

A study in the Journal of Clinical Investigation ties a heterozygous missense variant in thrombospondin 1 to childhood glaucoma.

Gene Co-Expression Database for Humans, Model Organisms Gets Update

GeneFriends has been updated to include gene and transcript co-expression networks based on RNA-seq data from 46,475 human and 34,322 mouse samples, a new paper in Nucleic Acids Research says.

New Study Investigates Genomics of Fanconi Anemia Repair Pathway in Cancer

A Rockefeller University team reports in Nature that FA repair deficiency leads to structural variants that can contribute to genomic instability.